These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37303969)

  • 41. [Ductal regeneration in vanishing bile duct syndrome in Hodgkin's lymphoma].
    Córdoba Iturriagagoitia A; Iñarrairaegui Bastarrica M; Pérez de Equiza E; Zozaya Urmeneta JM; Martínez-Peñuela JM; Beloqui Pérez R
    Gastroenterol Hepatol; 2005 May; 28(5):275-8. PubMed ID: 15871809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic-associated vanishing bile duct syndrome: a real-world retrospective and pharmacovigilance database analysis.
    Wang J; Wang S; Wu C; Deng Z
    Infection; 2024 Jun; 52(3):891-899. PubMed ID: 37996645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urosodeoxycholic Acid Therapy in a Child with Trimethoprim-Sulfamethoxazole-induced Vanishing Bile Duct Syndrome.
    Cho HJ; Jwa HJ; Kim KS; Gang DY; Kim JY
    Pediatr Gastroenterol Hepatol Nutr; 2013 Dec; 16(4):273-8. PubMed ID: 24511525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.
    Hubscher SG; Lumley MA; Elias E
    Hepatology; 1993 Jan; 17(1):70-7. PubMed ID: 7678577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
    Kochar R; Nevah MI; Lukens FJ; Fallon MB; Machicao VI
    World J Gastroenterol; 2010 Jul; 16(26):3335-8. PubMed ID: 20614492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-invasive biomarkers for identification of vanishing bile duct syndrome among children with acute cholestatic hepatitis.
    Wang NL; Chen L; Lin J; Lu Y; Fang WY; Xie XB; Wang JS
    Transl Pediatr; 2023 Oct; 12(10):1782-1790. PubMed ID: 37969129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic alpha-interferon expression in cytomegalovirus-infected liver allograft recipients with and without vanishing bile duct syndrome.
    Arnold JC; Nouri-Aria KT; O'Grady JG; Portmann BC; Alexander GJ; Williams R
    Clin Investig; 1993 Mar; 71(3):191-6. PubMed ID: 8386961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cloxacillin-induced acute vanishing bile duct syndrome: A case study and literature review.
    Faragalla K; Lau H; Wang HL; Liu J
    Br J Clin Pharmacol; 2022 Oct; 88(10):4633-4638. PubMed ID: 35730139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.
    Zhao Z; Bao L; Yu X; Zhu C; Xu J; Wang Y; Yin M; Li Y; Li W
    Medicine (Baltimore); 2017 Sep; 96(36):e8009. PubMed ID: 28885366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
    Fong M; Boyle S; Gutta N
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30796069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
    White JC; Appleman S
    Pediatrics; 2014 Oct; 134(4):e1194-8. PubMed ID: 25246624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hodgkin's lymphoma-related vanishing bile duct syndrome: a case report and literature review.
    Wong KM; Chang CS; Wu CC; Yin HL
    Kaohsiung J Med Sci; 2013 Nov; 29(11):636-41. PubMed ID: 24183359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome.
    Lv T; Yu H; Han X; Wee A; Liu J; Li M; Xu J; Hu X; Li J; Duan W; Wang T; Jia J; Zhao X
    J Clin Transl Hepatol; 2023 Oct; 11(5):1161-1169. PubMed ID: 37577216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute vanishing bile duct syndrome after the use of ibuprofen.
    Basturk A; Artan R; Yılmaz A; Gelen MT; Duman O
    Arab J Gastroenterol; 2016 Sep; 17(3):137-139. PubMed ID: 27658326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection.
    Delladetsima JK; Makris F; Psichogiou M; Kostakis A; Hatzakis A; Boletis JN
    Liver; 2001 Apr; 21(2):81-8. PubMed ID: 11318976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.
    Okan G; Yaylaci S; Peker O; Kaymakoglu S; Saruc M
    World J Gastroenterol; 2008 Aug; 14(29):4697-700. PubMed ID: 18698687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atypical primary biliary cholangitis results in vanishing bile duct syndrome with cutaneous xanthomas: a case report.
    Jia Y; Liu L; Deng B; Huang Y; Zhao J; Bai G
    Diagn Pathol; 2022 Jul; 17(1):57. PubMed ID: 35787279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin's lymphoma, fully reversible after chemotherapy.
    Leeuwenburgh I; Lugtenburg EP; van Buuren HR; Zondervan PE; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Feb; 20(2):145-7. PubMed ID: 18188038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-related Vanishing Bile Duct Syndrome (VBDS).
    Russe-Russe JR; Liu L; Thuluvath PJ
    J Clin Exp Hepatol; 2024; 14(2):101302. PubMed ID: 38544765
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug-induced Bile Duct Injury - A Short Review.
    Dobreva I; Karagyozov P
    Curr Drug Metab; 2020; 21(4):256-259. PubMed ID: 32310045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.